<DOC>
	<DOCNO>NCT00006118</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cisplatin , paclitaxel , gemcitabine treat patient progressive unresectable regional metastatic bladder cancer .</brief_summary>
	<brief_title>Cisplatin , Paclitaxel , Gemcitabine Treating Patients With Progressive Unresectable Regional Metastatic Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy toxicity cisplatin , paclitaxel , gemcitabine patient progressive unresectable regional metastatic transitional cell carcinoma bladder . - Determine progression free survival patient treat regimen . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 8 , cisplatin IV 1 hour paclitaxel IV 3 hour day 1 . Treatment repeat every 3 week 6 course . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 39 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive unresectable regional metastatic transitional cell carcinoma bladder Measurable disease CT MRI scan Greater 10 mm PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Not specify Renal : Creatinine le 1.36 mg/dL Cardiovascular : No uncontrolled cardiac disease No severe cardiac arrhythmia Other : Not pregnant nursing No prior malignancy except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Prior intravesical immunotherapy superficial disease allow No prior systemic biologic response modifier therapy advance disease Chemotherapy : Prior intravesical chemotherapy superficial disease allow No prior systemic chemotherapy advance disease Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : No prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>